StockData
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. (OKUR) shareholders

OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$2.58−0.17 (-6.18%)

Close on Nov 17, 2026Market cap $104.48MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
86.3%
35M of 40M shares
Institutional holders
75
32 new, 8 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
0 buys · 8 sales
Net sold $5.63K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Access Industries Holdings LLC
Joint filing with AI Biotechnology LLC (19.99%), Access Industries Management, LLC (19.99%) and 1 more
9,091,53219.99%13D (active)Mar 31, 2026
RA Capital Management, L.P.
Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more
4,038,7159.90%13G (passive)Mar 31, 2026
Anders Hove
Joint filing with Acorn Bioventures 2, L.P. (5.00%), Acorn Capital Advisors GP 2, LLC (5.00%)
3,924,0379.50%13G (passive)Mar 27, 2026
Lampert Mark N
Joint filing with Bvf Partners L P/Il (8.00%), Bvf Inc/Il (8.00%) and 1 more
3,235,7788.00%13G (passive) amendmentJun 30, 2026
Kevin Tang
Joint filing with Tang Capital Partners, LP (8.80%), Tang Capital Management, LLC (8.80%)
2,946,2608.80%13G (passive)Sep 26, 2024
Coastlands Capital GP LLC
Joint filing with Coastlands Capital LP (6.67%), Coastlands Capital Partners LP (6.67%) and 2 more
2,700,0006.67%13G (passive)Oct 1, 2026
StepStone VC MI-G GP, LLC
Joint filing with StepStone Group LP (6.60%), StepStone Master G, L.P. (6.60%)
2,660,6126.60%13G (passive)Mar 31, 2026
Daniel Schneeberger
Joint filing with ADAR1 Capital Management, LLC (5.50%)
2,238,6845.50%13G (passive) amendmentJun 30, 2026
Bvf Inc/Il
Joint filing with Bvf Partners L P/Il (5.30%), Lampert Mark N (5.30%)
2,134,9085.30%13G (passive)May 19, 2026
ADAR1 Capital Management, LLC
Joint filing with Daniel Schneeberger (7.90%), ADAR1 Capital Management GP, LLC (6.20%)
1,014,1587.90%13G (passive)Dec 31, 2025
Shay Capital Holdings LLC
Joint filing with Shay Capital LLC (6.30%)
810,2146.30%13G (passive)May 15, 2025
Prosight Partners, LLC
Joint filing with Prosight Management, LP (5.80%), W. Lawrence Hawkins (5.80%)
745,6495.80%13G (passive)Nov 24, 2025
CF Group Management, Inc.
Joint filing with Cantor Fitzgerald Securities (5.20%), Cantor Fitzgerald & Co. (5.20%) and 1 more
669,5395.20%13G (passive)Jun 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of OKURValueChange% of portfolio
Ra Capital Management, L.P.3,998,3339.87%$18.23M–0.16%
Bvf Inc/Il3,235,7787.99%$14.76M+1,256,8060.38%
Acorn Capital Advisors, LLC2,839,6747.01%$12.95M–3.53%
StepStone Group LP2,660,6126.57%$12.13M–0.56%
ADAR1 Capital Management, LLC2,238,6845.53%$10.21M−196,2570.47%
Vivo Capital, LLC1,927,7104.76%$8.79M–0.80%
Vestal Point Capital, LP1,825,6994.51%$8.33M−14,1200.19%
BlackRock, Inc.1,499,8453.70%$6.84M+1,450,2580.00%
Trails Edge Capital Partners, LP1,438,4563.55%$6.56MNew1.04%
Vanguard Capital Management LLC1,437,0393.55%$6.55M+854,5620.00%
Adage Capital Partners Gp, L.L.C.1,204,8192.98%$5.49M–0.01%
Citadel Advisors LLC1,187,0472.93%$5.41M+1,149,4600.00%
Sio Capital Management, LLC1,078,9652.66%$4.92M–0.81%
Prosight Management, LP978,9922.42%$4.46M−1,175,3890.77%
Logos Global Management LP963,8552.38%$4.40MNew0.19%
Geode Capital Management, LLC724,4381.79%$3.30M+625,6880.00%
NEA Management Company, LLC478,5481.18%$2.18M–0.14%
State Street Corp463,6621.14%$2.11M+450,2000.00%
Ensign Peak Advisors, Inc431,6311.07%$1.97MNew0.00%
Renaissance Technologies LLC358,7380.89%$1.64M−18,5120.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20267535M86.3%32 / 219 / 811M4M
Q1 20265128M68.0%18 / 1214 / 920M2M
Q4 20254411M27.4%8 / 916 / 63M2M
Q3 20254210M25.2%1 / 1513 / 80M1M
Q2 20254911M26.6%8 / 1613 / 64M5M
Q1 20254712M29.5%4 / 1513 / 81M1M
Q4 20245112M29.2%20 / 2010 / 1910M1M
Q3 2024513M7.1%7 / 1614 / 210M0M
Q2 2024663M6.9%21 / 1421 / 170M0M
Q1 2024623M6.9%12 / 1419 / 180M0M
Q4 2023683M6.3%27 / 1716 / 171M1M
Q3 2023583M6.8%10 / 2213 / 40M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

49 funds held OKUR in Q2 2026, 86% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of OKURValue% of fundAs of
Vanguard Total Stock Market Index Fund1,109,8232.74%$5.06M0.00%Jun 30, 2026
iShares Russell 2000 ETF483,1341.19%$2.20M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund302,4230.75%$1.38M0.00%Jun 30, 2026
Fidelity Small Cap Index Fund285,5100.71%$1.09M0.00%Jul 31, 2026
iShares Russell 2000 Value ETF193,8290.48%$883.86K0.01%Jun 30, 2026
iShares Micro-Cap ETF79,0840.20%$360.62K0.02%Jun 30, 2026
Schwab Small-Cap Index Fund63,6400.16%$243.10K0.00%Jul 31, 2026
Master Small Cap Index Series41,6520.10%$189.93K0.00%Jun 30, 2026
Fidelity Small Cap Value Index Fund36,5630.09%$166.73K0.01%Jun 30, 2026
Fidelity Extended Market Index Fund36,5300.09%$153.43K0.00%May 31, 2026
Nuveen Small Cap Blend Index Fund35,4020.09%$135.24K0.00%Jul 31, 2026
Ultra-Small Company Market Fund34,0000.08%$155.04K0.10%Jun 30, 2026
Dimensional U.S. Small Cap ETF32,4260.08%$123.87K0.00%Jul 31, 2026
EQ/2000 Managed Volatility Portfolio22,4170.06%$102.22K0.00%Jun 30, 2026
LVIP State Street Small-Cap Index Fund20,5000.05%$93.48K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Nicholas A. SaccomanoPresident and CEO, Director11,1600.03%Sep 23, 2026
Jason A. LeveroneChief Financial Officer18,5000.05%Sep 23, 2026
Dylan HartleyChief Scientific Officer––Aug 11, 2026
Samuel AgrestaChief Medical Officer––Aug 11, 2026
Isaac MankeDirector20,5830.05%Aug 13, 2026
Andrew John PhillipsDirector––Aug 11, 2026
Michael G. GreyDirector494,7621.22%Aug 11, 2026
R. Michael CarruthersDirector8740.00%Aug 11, 2026
Liam RatcliffeDirector––Aug 11, 2026
Valerie Malyvanh JansenDirector––Aug 11, 2026
Edward T. MathersDirector15,3100.04%Aug 11, 2026
Access Industries Management, Llc10% owner3,998,3329.87%Apr 7, 2026
Biotechnology LLC AI10% owner––Apr 7, 2026
Industries Holdings LLC Access10% owner––Apr 7, 2026
Len Blavatnik10% owner––Apr 7, 2026
Acorn Bioventures 2, L.P.10% owner––May 27, 2025
Acorn Capital Advisors GP 2, LLC10% owner1,129,7302.79%May 27, 2025
Anders D. Hove10% owner––May 19, 2025
Private Healthcare Fund III LP Cormorant–0–May 19, 2025
Cormorant Global Healthcare Master Fund, LP–1,813,4394.48%May 19, 2025
Private Healthcare Fund V. LP Cormorant–––May 19, 2025
Private Healthcare Fund IV LP Cormorant–––May 19, 2025
Acorn Capital Advisors Gp, Llc10% owner4,279,34810.57%May 19, 2025
Acorn Bioventures, L.P.10% owner––May 19, 2025
Bihua Chen–––May 19, 2025
Cormorant Asset Management, LP–––May 19, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Nicholas A. Saccomano
President and CEO, Director
Sep 21, 2026Sale−87$2.97$25811,160
Jason A. Leverone
Chief Financial Officer
Sep 21, 2026Sale−302$2.97$89718,500
Nicholas A. Saccomano
President and CEO, Director
Jun 22, 2026Sale−86$4.40$37811,247
Jason A. Leverone
Chief Financial Officer
Jun 22, 2026Sale−303$4.40$1.33K18,802
Jason A. Leverone
Chief Financial Officer
Mar 23, 2026Sale−301$4.16$1.25K16,000
Nicholas A. Saccomano
President and CEO, Director
Mar 23, 2026Sale−86$4.16$3587,333
Isaac Manke
Director
Dec 31, 2025Award+5,258––20,583
Edward T. Mathers
Director
Dec 31, 2025Award+3,911––15,310
Nicholas A. Saccomano
President and CEO, Director
Dec 22, 2025Sale−87$2.97$2587,419
Jason A. Leverone
Chief Financial Officer
Dec 22, 2025Sale−302$2.97$89716,301
Isaac Manke
Director
Sep 30, 2025Award+5,545––15,325
Edward T. Mathers
Director
Sep 30, 2025Award+4,125––11,399
Nicholas A. Saccomano
President and CEO, Director
Sep 22, 2025Sale−88$2.62$2313,506
Jason A. Leverone
Chief Financial Officer
Sep 22, 2025Sale−303$2.62$79412,603
Edward T. Mathers
Director
Jun 30, 2025Award+4,694––7,274
Isaac Manke
Director
Jun 30, 2025Award+6,311––9,780
Nicholas A. Saccomano
President and CEO, Director
Jun 23, 2025Sale−88$2.38$2093,594
Jason A. Leverone
Chief Financial Officer
Jun 23, 2025Sale−303$2.38$72112,906
Acorn Capital Advisors Gp, Llc
10% owner
May 15, 2025Buy+270,270$1.85$500.00K1,709,944
Acorn Capital Advisors Gp, Llc
10% owner
May 15, 2025Buy+1,129,730$1.85$2.09M1,129,730
Private Healthcare Fund III LP Cormorant
–
May 15, 2025Sale−1,813,439$1.85$3.35M0
Cormorant Global Healthcare Master Fund, LP
10% owner
May 12, 2025Sale−24,300$1.99$48.36K1,813,439
Nicholas A. Saccomano
President and CEO, Director
Apr 7, 2025Sale−516$2.67$1.38K3,682
Jason A. Leverone
Chief Financial Officer
Apr 7, 2025Sale−1,844$2.67$4.92K13,209
Nicholas A. Saccomano
President and CEO, Director
Apr 4, 2025Sale−358$3.33$1.19K4,198
Jason A. Leverone
Chief Financial Officer
Apr 4, 2025Sale−1,278$3.33$4.26K15,053
Isaac Manke
Director
Mar 31, 2025Award+3,469––3,469
Edward T. Mathers
Director
Mar 31, 2025Award+2,580––2,580
Braden Michael Leonard
–
Oct 7, 2024Other+345,739––345,739
Braden Michael Leonard
–
Oct 7, 2024Other+102,076––102,076
Jason A. Leverone
Chief Financial Officer
Oct 4, 2024Award+16,331––16,331
Nicholas A. Saccomano
President and CEO, Director
Oct 4, 2024Award+4,556––4,556
R. Michael Carruthers
Director
Oct 4, 2024Award+874––874
R. Michael Carruthers
Director
Oct 4, 2024Award+4,065––4,939
Braden Michael Leonard
10% owner
Sep 25, 2024Buy+68,746$1.50$103.12K3,457,395
Braden Michael Leonard
10% owner
Sep 24, 2024Buy+29,600$1.41$41.74K3,388,649
Braden Michael Leonard
10% owner
Sep 18, 2024Buy+806$1.40$1.13K3,359,049
Braden Michael Leonard
10% owner
Sep 17, 2024Buy+55,300$1.36$75.21K3,358,243
Braden Michael Leonard
10% owner
Sep 16, 2024Buy+172,747$1.37$236.66K3,302,943
Braden Michael Leonard
10% owner
Sep 13, 2024Buy+150,000$1.31$196.50K3,130,196
Braden Michael Leonard
10% owner
Sep 12, 2024Buy+36,176$1.40$50.65K2,980,196
Braden Michael Leonard
10% owner
Aug 14, 2024Buy+100,487$1.41$141.69K2,944,020
Braden Michael Leonard
10% owner
Aug 13, 2024Buy+171,339$1.39$238.16K2,843,533
Braden Michael Leonard
10% owner
May 14, 2024Buy+335,000$1.54$515.90K2,672,194
Braden Michael Leonard
10% owner
May 14, 2024Buy+79,281$1.56$123.68K2,337,194
Ashley Hall
Chief Development Officer
Aug 28, 2023Option exercise+15,625$1.80$28.13K55,225
Ashley Hall
Chief Development Officer
Aug 28, 2023Sale−15,625$6.28$98.13K39,600
Michael G. Grey
Executive Chairman, Director
Jul 26, 2023Gift−50,000––0
Holdings A/S Novo
10% owner
Jun 23, 2023Sale−100,000$7.10$710.00K3,330,337
Niall O'Donnell
Director
May 8, 2023Buy+125,000$8.00$1.00M2,188,713
Michael Cruse
Chief Operating Officer
Sep 1, 2022Buy+7,500$3.39$25.43K13,697
Michael G. Grey
Executive Chairman, Director
Aug 31, 2022Option exercise+50,000$1.97$98.50K50,000
Michael Cruse
Chief Operating Officer
Aug 31, 2022Buy+3,212$3.21$10.31K6,197
Michael Cruse
Chief Operating Officer
Aug 30, 2022Buy+1,845$3.19$5.89K2,985
Michael Cruse
Chief Operating Officer
Aug 30, 2022Buy+975$3.16$3.08K31,758
Michael Cruse
Chief Operating Officer
Aug 29, 2022Buy+1,140$3.24$3.69K1,140
Michael Cruse
Chief Operating Officer
Aug 29, 2022Buy+83$3.24$26930,783
Alejandro Dorenbaum
Chief Medical Officer
Aug 12, 2022Gift−22,348––30,000
Alejandro Dorenbaum
Chief Medical Officer
Dec 10, 2021Award+30,000––52,348
Michael Cruse
Senior VP-Corporate Operations
Dec 10, 2021Award+25,000––29,100

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
4.86%
1M shares short
Days to cover
4.2
At 0M shares a day
Change since last report
-6.3%
From 1M shares
Short volume, 20 days
30.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of OnKure Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,960 shares on Sep 24, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Hall Ashley
Officer
Aug 28, 202315,625$98.06KAug 28, 2023STOCK OPTION EXERCISE
Novo Holdings A/S
10% Stockholder
Jun 23, 2023100,000$735.00KJun 23, 2023Purchase of stock in the Issuer's IPO

See a number that looks wrong?